These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2730278)
21. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression. Klaassen T; Riedel WJ; van Praag HM; Menheere PP; Griez E Psychiatry Res; 2002 Dec; 113(1-2):29-40. PubMed ID: 12467943 [TBL] [Abstract][Full Text] [Related]
22. Central serotonergic hyperresponsivity in late-onset Alzheimer's disease. McLoughlin DM; Lucey JV; Dinan TG Am J Psychiatry; 1994 Nov; 151(11):1701-3. PubMed ID: 7943465 [TBL] [Abstract][Full Text] [Related]
23. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Kahn RS; Kalus O; Wetzler S; Cahn W; Asnis GM; van Praag HM Psychiatry Res; 1990 Aug; 33(2):189-98. PubMed ID: 2243896 [TBL] [Abstract][Full Text] [Related]
24. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Seibyl JP; Krystal JH; Price LH; Woods SW; D'Amico C; Heninger GR; Charney DS Psychiatry Res; 1991 Sep; 38(3):227-36. PubMed ID: 1754635 [TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. Mueller EA; Murphy DL; Sunderland T J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985 [TBL] [Abstract][Full Text] [Related]
26. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers. Sabbe B; Hulstijn W; Maes M; Pier M; Scharpé S; Zitman F Psychiatry Res; 2001 Dec; 105(3):151-63. PubMed ID: 11814535 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Feuchtl A; Bagli M; Stephan R; Frahnert C; Kölsch H; Kühn KU; Rao ML Pharmacopsychiatry; 2004 Jul; 37(4):180-8. PubMed ID: 15467976 [TBL] [Abstract][Full Text] [Related]
28. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Goddard AW; Woods SW; Money R; Pande AC; Charney DS; Goodman WK; Heninger GR; Price LH Psychiatry Res; 1999 Mar; 85(3):225-40. PubMed ID: 10333376 [TBL] [Abstract][Full Text] [Related]
29. A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects. Kalus O; Wetzler S; Kahn RS; Asnis GM; van Praag HM Psychopharmacology (Berl); 1992; 106(3):388-90. PubMed ID: 1533289 [TBL] [Abstract][Full Text] [Related]
30. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Levitan RD; Kaplan AS; Joffe RT; Levitt AJ; Brown GM Arch Gen Psychiatry; 1997 Jun; 54(6):521-7. PubMed ID: 9193192 [TBL] [Abstract][Full Text] [Related]
31. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Kahn RS; Wetzler S; Asnis GM; Kling MA; Suckow RF; van Praag HM Psychopharmacology (Berl); 1990; 100(3):339-44. PubMed ID: 2156278 [TBL] [Abstract][Full Text] [Related]
32. Differential neuroendocrine responses to the 5-HT agonist m-chlorophenylpiperazine in Fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. Aulakh CS; Wozniak KM; Hill JL; Devane CL; Tolliver TJ; Murphy DL Neuroendocrinology; 1988 Oct; 48(4):401-6. PubMed ID: 2463494 [TBL] [Abstract][Full Text] [Related]
33. Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Handelsman L; Kahn RS; Sturiano C; Rinaldi PJ; Gabriel S; Schmeidler JP; Bernstein DP; Siever L; Cooper TB Psychiatry Res; 1998 Jul; 80(1):1-12. PubMed ID: 9727959 [TBL] [Abstract][Full Text] [Related]
34. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593 [TBL] [Abstract][Full Text] [Related]
35. Serotonin function and treatment response to clozapine in schizophrenic patients. Kahn RS; Davidson M; Siever L; Gabriel S; Apter S; Davis KL Am J Psychiatry; 1993 Sep; 150(9):1337-42. PubMed ID: 8394651 [TBL] [Abstract][Full Text] [Related]
36. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283 [TBL] [Abstract][Full Text] [Related]
37. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. Lawlor BA; Sunderland T; Mellow AM; Hill JL; Newhouse PA; Murphy DL Biol Psychiatry; 1989 Mar; 25(6):679-86. PubMed ID: 2923931 [TBL] [Abstract][Full Text] [Related]
38. 5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. Leone M; Attanasio A; Croci D; Ferraris A; D'Amico D; Grazzi L; Nespolo A; Bussone G Neuroreport; 1998 Aug; 9(11):2605-8. PubMed ID: 9721941 [TBL] [Abstract][Full Text] [Related]
39. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. de Leeuw AS; Westenberg HG J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183 [TBL] [Abstract][Full Text] [Related]
40. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]